MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa2515458

Медицинская библиотека · The New England journal of medicine · 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Al-Sawaf Othman, Stumpf Janina, Zhang Can, Simon Florian, Bosch Francesc, Feyzi Emadoldin, Ghia Paolo, Gregor Michael, Kater Arnon P, Lindström Vesa, Mattsson Mattias, Niemann Carsten U, Staber Philipp B, Tadmor Tamar, Thornton Patrick, Wendtner Clemens-Martin, Janssens Ann, Noesslinger Thomas, Bohn Jan-Paul, da Cunha-Bang Caspar, Poulsen Christian B, Ranti Juha, Illmer Thomas, Schoettker Bjoern, Böttcher Sebastian, Gaska Tobias, Vandenberghe Elisabeth, Clifford Ruth, Benjamini Ohad, Frustaci Anna Maria, Scarfò Lydia, Sportoletti Paolo, Schreurs John, Levin Mark-David, van der Straaten Hanneke, van der Klift Marjolein, Tran Hoa, de la Serna Javier, Loscertales Javier, Lindblad Oscar, Bergendahl Sandstedt Anna, Goede Jeroen, Baumann Michael, Fink Anna Maria, Fischer Kirsten, Ritgen Matthias, Kreuzer Karl-Anton, Schneider Christof, Tausch Eugen, Stilgenbauer Stephan, Robrecht Sandra, Eichhorst Barbara, Hallek Michael, CLL17 Trial Investigators

Клиническое исследование III фазыEquivalence TrialСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches - continuous therapy with Bruton's tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax with either CD20 antibodies or Bruton's tyrosine kinase inhibitors. Comparisons of these two therapeutic approaches are lacking.

METHODS

We conducted an investigator-initiated, phase 3, randomized trial involving patients with previously untreated CLL. Patients were randomly assigned to receive continuous ibrutinib or fixed-duration venetoclax-obinutuzumab or venetoclax-ibrutinib. The primary end point was investigator-assessed progression-free survival (noninferiority margin for the hazard ratio, 1.608, corresponding to a noninferiority margin of 8 percentage points at 3 years). Secondary end points included minimal residual disease (MRD), response, overall survival, and safety.

RESULTS

A total of 909 patients were assigned to venetoclax-obinutuzumab (303 patients), venetoclax-ibrutinib (305 patients), or ibrutinib (301 patients). The median follow-up was 34.2 months. In this prespecified interim analysis, 3-year progression-free survival was 81.1% in the venetoclax-obinutuzumab group, 79.4% in the venetoclax-ibrutinib group, and 81.0% in the ibrutinib group (hazard ratio for venetoclax-obinutuzumab vs. ibrutinib, 0.87 [98.3% confidence interval {CI}, 0.54 to 1.41]; hazard ratio for venetoclax-ibrutinib vs. ibrutinib, 0.84 [98.0% CI, 0.53 to 1.32]); the results for each comparison met the criterion for noninferiority. After the end of treatment, MRD in peripheral blood was undetectable in 73.3% of the patients in the venetoclax-obinutuzumab group, 47.2% in the venetoclax-ibrutinib group, and 0% in the ibrutinib group. Three-year overall survival was 91.5%, 96.0%, and 95.7%, respectively. The most common adverse events were infections, gastrointestinal disorders, and cytopenias.

CONCLUSIONS

In patients with previously untreated CLL, fixed-duration treatment with venetoclax-obinutuzumab or venetoclax-ibrutinib was noninferior to continuous ibrutinib with regard to investigator-assessed progression-free survival. (Funded by the University of Cologne and others; CLL17 ClinicalTrials.gov number, NCT04608318; EudraCT number, 2019-003854-99.).

Для цитирования: Al-Sawaf Othman, Stumpf Janina, Zhang Can, Simon Florian, Bosch Francesc, Feyzi Emadoldin, Ghia Paolo, Gregor Michael, Kater Arnon P, Lindström Vesa, Mattsson Mattias, Niemann Carsten U, Staber Philipp B, Tadmor Tamar, Thornton Patrick, Wendtner Clemens-Martin, Janssens Ann, Noesslinger Thomas, Bohn Jan-Paul, da Cunha-Bang Caspar, Poulsen Christian B, Ranti Juha, Illmer Thomas, Schoettker Bjoern, Böttcher Sebastian, Gaska Tobias, Vandenberghe Elisabeth, Clifford Ruth, Benjamini Ohad, Frustaci Anna Maria, Scarfò Lydia, Sportoletti Paolo, Schreurs John, Levin Mark-David, van der Straaten Hanneke, van der Klift Marjolein, Tran Hoa, de la Serna Javier, Loscertales Javier, Lindblad Oscar, Bergendahl Sandstedt Anna, Goede Jeroen, Baumann Michael, Fink Anna Maria, Fischer Kirsten, Ritgen Matthias, Kreuzer Karl-Anton, Schneider Christof, Tausch Eugen, Stilgenbauer Stephan, Robrecht Sandra, Eichhorst Barbara, Hallek Michael, CLL17 Trial Investigators. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.. The New England journal of medicine. 2025. DOI: 10.1056/nejmoa2515458.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.